Sabah Al-Harazi¹*, Lubna Shirin² and Mohammed Shahjahan Kabir³

¹Department of Early Clinical Exposure, Faculty of Medicine, Malaysian Allied Health Sciences Academy (MAHSA) University, Malaysia

*Corresponding Author: Sabah Al-Harazi, Department of Early Clinical Exposure, Faculty of Medicine, Malaysian Allied Health Sciences Academy (MAHSA) University, Malaysia, ORCID ID: 0000-0002-1183-089X.

Received: May 05, 2022; Published: June 06, 2022

Abstract

Infections caused by bacteria, viruses, and fungi have been reported in COVID-19 patients, but data on these infections is limited. These infections are classified as either community-acquired or hospital-acquired and coinfection or secondary/superinfection. The most common hospital-acquired superinfections are ventilator-associated pneumonia, hospital-acquired pneumonia, and bacteremia. The prevalence of community-acquired bacterial pneumonia in patients with COVID-19 infection is uncommon. Co-infection with COVID-19 and tuberculosis (TB) has also been reported. Empiric antibiotics may not be required in the majority of COVID-19 patients, especially those not severely ill. Superinfections by antibiotic-resistant bacteria have also been reported among critically ill patients with COVID-19 infection.

Keywords:Bacteria; Coronavirus Disease 2019; Community-acquired Infections; Hospital-acquired Infections

References

1. Garner JS., et al. "CDC definitions for nosocomial infections, 1988". AJIC American Journal of Infection Control 3 (1988): 128-140.
2. Henderson KL., et al. "Community-acquired, healthcare-associated and hospital-acquired bloodstream infection definitions in children: a systematic review demonstrating inconsistent criteria". Journal of Hospital Infection 2 (2013): 94-105.
3. Søgaard KK., et al. "Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia". Journal of Intensive Care1 (2021): 10.
4. Baskaran V., et al. "Co-infection in critically ill patients with COVID-19: an observational cohort study from England". Journal of Medical Microbiology4 (2021): 001350.
5. Garcia-Vidal C., et al. "Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study". Clinical Microbiology and Infection 1 (2021): 83-88.
6. Woo Joo Kwon, et al. "Superinfections and Coinfections in COVID-19".| MedPage Today (2020).
7. Huang C., et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet10223 (2020): 497-506.
8. Zhu X., et al. "Co-infection with respiratory pathogens among COVID-2019 cases". Virus Research 285 (2020): 198005.
9. Lai C-C., et al. "Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?". Journal of Microbiology, Immunology and Infection 4 (2020): 505-512.
10. Lansbury L., et al. "Co-infections in people with COVID-19: a systematic review and meta-analysis". Journal of Infection2 (2020): 266-275.
11. Musuuza J., et al. "Prevalence and outcomes of co-infection and super-infection with SARS-CoV-2 and other pathogens: A Systematic Review and Meta-analysis". PLoS One5 (2021): e0251170.
12. Langford BJ., et al. "Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis". Clinical Microbiology and Infection 12 (2020): 1622-1629.
13. National Institute for Health and Care Excellence (NICE). "COVID-19 rapid guideline: Managing COVID-19". (2022).
14. Nasir N., et al. "Risk factors for bacterial infections in patients with moderate to severe COVID-19: A case-control study". Journal of Medical Virology7 (2021): 4564-4569.
15. He Y., et al. "Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China". Infection Control and Hospital Epidemiology 8 (2020): 982-983.
16. Puzniak L., et al. "A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19". BMC Infectious Disease1 (2021): 227.
17. Maes M., et al. "Ventilator-associated pneumonia in critically ill patients with COVID-19". Critical Care1 (2021): 25.
18. COVID-19 Treatment Guidelines Panel. “Coronavirus Disease 2019 (COVID-19) Treatment Guidelines”. National Institutes of Health (NIH).
19. Contou D., et al. "Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU". Annals of Intensive Care1 (2020): 119.
20. Tadolini M., et al. "Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases". European Respiratory Journal1 (2020): 2001398.
21. Visca D., et al. "Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects". Pulmonology2 (2021): 151-165.
22. World Health Organization (WHO). "Information Note Tuberculosis and COVID-19 COVID-19: Considerations for tuberculosis (TB) care" (2020).
23. Sy KTL., et al. "Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19". Infectious Disease (Lond) 12 (2020): 902-907.
24. Davies M-A. "HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa". org - the preprint server for Health Sciences 7.2 (2020): 20145185.
25. Mishra A., et al. "Tuberculosis and COVID-19 Co-infection: An Updated Review". Acta Biomed1 (2020): e2021025.
26. Motta I., et al. "Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts". Pulmonology4 (2020): 233-240.
27. Togun T., et al. "Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes”. Annals of Clinical Microbiology and Antimicrobials21 (2020): 1-6.
28. Chen N., et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet10223 (2020): 507-513.
29. Yang X., et al. "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". Lancet Respiratory Medicine5 (2020): 475-481.
30. Zhou F., et al. "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". Lancet10229 (2020): 1054-1062.
31. Clancy CJ., et al. "Bacterial superinfections among persons with coronavirus disease 2019: A comprehensive review of data from postmortem studies". Open Forum Infectious Diseases 3 (2021): ofab065.
32. Nag VL., et al. "Superinfections in COVID-19 Patients: Role of Antimicrobials". Dubai Medical Journal1 (2021): 1-10.

Citation

Citation: Sabah Al-Harazi., et al. “Bacterial Infections in Coronavirus Disease 2019". Acta Scientific Microbiology 5.7 (2022): 15-21.

Copyright

Copyright: © 2022 Sabah Al-Harazi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.